Our aim is to understand the means cancer cells use to develop resistance to cancer therapies. Our special focus are the mechanisms that enable the establishment of minimal residual disease, or govern the maintenance of residual tumors following targeted cancer therapy. The overarching goal of our research is to develop rational combination strategies that will extend the long-term efficacy of clinically used cancer therapies. The research group is led by Kari Kurppa.

Read more: https://sites.utu.fi/kurppalab/